Short Selling's Shaky Testimony: Implications for the Market and Its Players The recent testimony of Cronos CEO Mike Gorenstein at the US trial of Citron Research founder Andrew Left has brought the world of short selling into sharp relief.
While the specifics of this case are unique, they raise important questions about the role of short sellers in the market and their impact on publicly traded companies.
Gorenstein's testimony that Left's report on Cronos "didn't make much sense" highlights the potential for inaccurate or misleading research to influence investors' decisions.